SoftBank-backed cancer immunotherapy developer ICT has collected series C funding from CDH Investments’ CDH VGC unit.
Innovative Cellular Therapeutics (ICT), a China-based cancer immunotherapy developer backed by internet and telecommunications group SoftBank, has raised over $40m in a series C round led by asset manager CDH Investments, DealStreetAsia reported yesterday.
CDH led the financing through its venture capital subsidiary, CDH Venture and Growth Capital.
Founded in 2009, ICT is working on a number of cellular immunotherapies for the treatment of solid and liquid tumours. It operates a proprietary CAR-T cell technology platform to develop its treatments.
…
